Abstract
After the declaration of coronavirus as a pandemic in 2019, a strong relationship has been shown between the sudden upsurge of mucormycosis occurrence in patients with history of COVID-19. This relation can be explained by the effect of coronavirus on the patient's immune system, the infection worsens the effect of the underlying predisposing factors such as diabetes mellitus and drugs therapies that were used in the treatment of COVID-19, especially corticosteroids. Mucormycosis presented mainly in patients who had comorbid conditions like diabetes, steroid therapy, or chemotherapy. This study showed the association between the increase in the prevalence of mucormycosis in patients with COVID-19 and proved that dia-betes was the main risk factor for this fungal infection. The study confirmed that many factors determined the prognosis in the management of mucormycosis, first of them is the early diagnosis which depends on a high index of clinical suspicion, accurate procedures for diagnosis confirmation such as biopsy, fungal culture media, radiological examination by computed tomography scan or magnetic resonance imaging, early initiation of antifungal therapy either Amphotericin-B or Liposomal Amphotericin-B as soon as the diagnosis is confirmed and aggressive surgical debridement of all infected tissues (Figure 1).